Læknablaðið : fylgirit - 01.06.1999, Blaðsíða 26

26
LÆKNABLAÐIÐ 1999; 85/FYLGIRIT 38
HEIMILDIR
1. Heilbrigðis- og tryggingamálaráðuneytið, lyfjamáladeild.
Sala lyfja á íslandi og Norðurlöndum. Töflur og myndir í
handriti 1999.
2. Starfshópur heilbrigðis- og tryggingamálaráðherra. Stefnu-
mótun í málefnum geðsjúkra. Skýrsla starfshóps heilbrigð-
is- og tryggingamálaráðherra. Reykjavík: Heilbrigðis- og
tryggingamálaráðuneytið, október 1998.
3. Staðtölur almannatrygginga 1996. Reykjavík: Trygginga-
stofnun ríkisins. Hagdeild 1997: 3.
4. Helgason T. The prevalence of minor mental disorders and
the prescribing of antidepressants and tranquillizers in
Reykjavík in 1984. Psychiatria Fennica 1991; 22: 113-22.
5. Robins LN, Helzer JE, Weissman MM, Orvaschel H,
Gruenberg E, Burke JD, et al. Lifetime prevalence of
specific psychiatric disorders in three sites. Arch Gen
Psychiatry 1984; 41: 949-58.
6. Stefánsson JG, Líndal E, Björnsson JK, Guðmundsdóttir A.
Lifetime prevalence of specifíc mental disorders among
people born in Iceland in 1931. Acta Psychiatr Scand 1991;
84: 142-9.
7. Stefánsson JG, Líndal E, Bjömsson JK, Guðmundsdóttir A.
Period prevalence rates of specific mental disorders in an
Icelandic cohort. Soc Psychiatry Psychiatr Epidemiol 1994;
29: 119-25.
8. Magnússon H. Mental health of octogenarians in Iceland.
Acta Psychiatr Scand 1989; 79/Suppl. 349.
9. Helgason T. Depressionernes epidemiologi. Nord Psykiatr
Tidsskr 1990; 44: 3-12.
10. AHCPR (Agency for Health Care Policy and Research).
Treatment of depression- Newer pharmacotherapies. Sum-
mary, Evidence Report/Technology Assessment: Number 7,
March 1999. http::/www.ahcpr.gov/clinic/deprsumm.htm.
11. Crott R, Gilis P. Economic comparisons of the pharmaco-
therapy of depression: an overview. Acta Psychiatr Scand
1998; 97: 241-52.
12. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant
treatment reassessed. Br J Psychiatry 1997; 170: 257-63.
13. Public Health Common Data: Incorporating Indicators
from „The Health of the Nation“: 1992: England. Univer-
sity of Surrey, Institute of Public Health 1993. Cited in 2.
14. Murray CJL, Lopez AD (eds.) The Global Burden of Dis-
ease. A Comprehensive Assessment of Mortality and Dis-
ability from Diseases, Injuries, and Risk Factors in 1990
and Projected. Boston: Harvard University Press 1996.
Cited in 2.
15. Lapierre Y, Bentkover J, Schainbaum S, Manners S. Direct
cost of depression: analysis of treatment costs of paroxetine
versus imipramine in Canada. Can J Psychiatry 1995; 40:
370-7.
16. The ICD-10 classification of mental and behavioural disor-
ders: diagnostic criteria for research. Geneva: World Health
Organization 1993.
17. Dubovsky SL, Buzan R. Mood Disorders. In: Hales RE,
Yudofsky SC, Talbot JA, eds. Textbook of Psychiatry. 3rd
ed. Washington DC: The American Psychiatric Press 1999:
479-566.
18. Burke MJ, Preskorn S. Short-term treatment of mood disor-
ders with standard antidepressants. In: Bloom FE, Kupfer
DJ, eds. Psychopharmacology. New York: Raven Press
1995: 1053-65.
19. American Psychiatric Association: practice guidelines for
treatment of major depression in adults. Am J Psychiatry
1993; 150/Suppl. 4.
20. The ICD-10 classification of mental and behavioural disor-
ders: clinical descriptions and diagnostic guidelines. Geneva:
World Health Organization 1992.
21. Meredith SL. Counseling typically provided for depression:
role of clinician speciality and payment system. Arch Gen
Psychiatry 1996; 53: 905-12.
22. Schulberg HC. Treating major depression in primary care
practice: eight-month clinical outcomes. Arch Gen Psy-
chiatry 1996;53:913-9.
23. Yapko, Michael D. Hand me down the blues. New York:
Golden Books 1999.
24. Sérlyfjaskrá 1999. Reykjavík: Heilbrigðis- og trygginga-
málaráðuneytið 1999.
25. Spigset O, Mártensson B. Drug treatment of depression. Br
MedJ 1999; 318: 1188-91.
26. Edwards JG. Long term pharmacotherpy of depression. Br
MedJ 1998; 316: 1180-1.
27. Eisenberg L. Treating depression and anxiety in primary
care. N Engl J Med 1992; 326: 1080-3.
28. Helgason T. Prescribing of psychotropic drugs by primary
care physicians and psychiatrists. In: Cooper B, Eastwood
R, eds. Primary health care and psychiatric epidemiology.
London, New York: Tavistock/Routledge 1992; 198-209.
29. Donoghue JM, Tylee A. The treatment of depression: pre-
scribing patterns of antidepressants in primary care in the
UK. Br J Psychiatry 1996; 168: 164-8.
30. Donoghue J. Suboptimal use of tricyclic antidepressants in
primary care. Acta Psychiatr Scand 1998; 98: 429-31.
31. Tryggingastofnun ríkisins. Töflur um lyfjaávísanir. I hand-
riti 1999.
32. Helgason T, Bjömsson JK, Zoéga T, Þorsteinsson HS, Tóm-
asson T. Psychopharmacoepiedmiology in Iceland: effects
of regulations and new medications. Eur Arch Psychiatry
Clin Neurosci 1997; 247: 93-9.
33. Rosholm J-U, Hallas J, Gram LF. Outpatient utilization of
antidepressants: a prescription database analysis. J Affect
Disorders 1993; 27: 21-8.
34. Bingefors KAL, Isacson DGL, von Knorring L, Smedby B.
Prescription drug and health care use among Swedish
patients treated with antidepressants. Ann Pharmacother
1995; 29: 566-72.
35. Isometsá E, Seppálá I, Henriksson M, Kekki P, Lönnquist J.
Inadequate dosaging in general practice of tricyclic vs.
other antidepressants for depression. Acta Pssychiatr Scand
1998;98:451-4.
36. Jónasson B. Munnlegar upplýsingar, apríl 1999.
37. Þorsteinsson JB. Geðræn vandamál í heilsugæslunni.
Gæðaþróunarverkefni 22 heilsugæslu- og heimilislækna
[ágrip]. 4. Vísindaþing Félags íslenskra heimilislækna 1998;
59. Reykjavík, nóvember 1998.
38. Beck HJ. Munnlegar upplýsingar í mars 1999.
39. Nefnd um könnun á tíðni og orsökum sjálfsvíga á íslandi.
Könnun á tfðni og orsökum sjálfsvíga á Islandi og tillögur
til úrbóta. Reykjavík: Menntamálaráðuneytið 1996
40. Hagstofa íslands. Upplýsingar um sjálfsvíg, bráðabirgðatöl-
urfyrir 1996. Apríl 1999.
41. Helgason T, Björnsson JK, Tómasson K, Einarsson GV,
Harðarson Þ, Jónsson H. Health-related quality of life in
psychiatric and other patients before and after treatment.
Eur Psychiatry 1998; 13/Suppl. 4: 319s.
42. Wolfe SM. Why do American drug companies spend more
than $12 billion a year pushing drugs? Is it education or
promotion? J Gen Intem Med 1996; 11: 637-9.
43. Devlin J, Hemsley P. Management views on industry is-
sues, pressures and consultants. Scrip Magazine 1997;
(June 16): 183. IMS America Press Release March 31,
1998.
44. Götzsche PC. Lægerne vælger den dyre medicin. http://
www.netdoktor.dk. Mars 1999
45. Félag íslenskra heimilislækna, heilbrigðis- og trygginga-
málaráðuneytið, landlæknir, Tryggingastofnun ríkisins.
LyQaval. Reykjavík: Tryggingastofnun ríkisins 1995.
46. Helgason T. Faraldsfræðilegar rannsóknir í geðlæknisfræði
áíslandi. Læknablaðið 1994; 80: 155-64.